modelTegafurCombinations
Extends from Pharmacolibrary.Drugs.ATC.L.L01BC53.
Information
| name: | TegafurCombinations | |
| ATC code: | L01BC53 | route: | oral |
| compartments: | 2 | |
| dosage: | 40 | mg |
| volume of distribution: | 48 | L |
| clearance: | 11.5 | L/h |
| other parameters in model implementation | ||
Tegafur, in combinations (ATC L01BC53), is an oral chemotherapeutic agent used mainly in conjunction with other agents such as uracil or gimeracil and oteracil (as S-1 formulation) for the treatment of various solid tumors, especially gastric and colorectal cancer. It is a prodrug of 5-fluorouracil (5-FU) that is bioactivated in the body, and these combinations are approved and still in clinical use for several cancer indications.
Pharmacokinetics
Pharmacokinetic parameters reported for adult cancer patients (mixed sex, typical age range 40-70 years) receiving S-1 (tegafur/gimeracil/oteracil) orally.
References
Kobuchi, S, et al., & Sakaeda, T (2018). Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 123 452–458. DOI:10.1016/j.ejps.2018.08.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30077713
Zuo, L, et al., & Chen, R (2024). Establishment and validation of a population pharmacokinetic model for apatinib in patients with tumors. BMC cancer 24(1) 1346–None. DOI:10.1186/s12885-024-13118-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39487410
Shirao, K, et al., & Abbruzzese, JL (2004). Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(17) 3466–3474. DOI:10.1200/JCO.2004.05.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15277535
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.TransferRate | ka (from PK_2C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_2C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)